Table 5.

Adjusted HR and 95% CI of aspirin use, frequency, and duration associated with NSCLC survival in the NCI-Maryland NSCLC Case–Control Study, among only AA

ModelaModelb
Aspirin useHR (95% CI)PHR (95% CI)P
NoReferenceReference
Yes0.66 (0.47–0.93)0.020.64 (0.45–0.91)0.01
Daily aspirin use
 NeverReferenceReference
 < 1 tablet per day0.97 (0.38–2.47)0.950.98 (0.38–2.54)0.97
 ≥ 1 tablet per day0.64 (0.44–0.91)0.010.61 (0.42–0.90)0.01
 Trend0.010.01
Duration of aspirin use
 NeverReferenceReference
 <3 years0.55 (0.31–1.00)0.050.53 (0.29–1.00)0.05
 ≥3 years0.62 (0.42–0.93)0.020.60 (0.39–0.92)0.02
 Trend0.010.01
  • aAdjusted for age, gender, smoking, pack-years, education, marital status, year of interview, use of Tylenol and other NSAIDs, stage, histology, and BMI at diagnosis.

  • bAdjusted for age, gender, smoking, pack-years, education, BMI, marital status, year of interview, use of Tylenol and other NSAIDs, stage, histology, BMI at diagnosis, and global genetic ancestry.

  • Bold values denote statistical significance.